20 July 2026
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Asher Rubin Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Nick DeAngelis Lead | Sidley | Not stated | M&A | Not stated |
| Istvan Hajdu Lead | Sidley | Not stated | Capital Markets | Not stated |
| Alison Lehner | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Andrea Reed | Sidley | Not stated | Corporate Governance | Not stated |
| Karim Pirani | Sidley | Not stated | Employee Benefits and Executive Compensation | Not stated |
| Molly Homann | Sidley | Not stated | M&A | Not stated |
| Kelly Katherine Ball | Sidley | Not stated | M&A | Not stated |
| Amanda Chong Artese | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Henry Dickinson | Sidley | Not stated | Capital Markets | Not stated |
| Christian Brause | Sidley | Not stated | Tax | Not stated |
| Daniel Venetucci | Sidley | Not stated | Tax | Not stated |
9 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 320m (US$320 million)
- What the figure measures
- Issue size
- Client
- NextCure, Inc.Buy-side
- Counterparties
- Avere Therapeutics, Inc. (Sell-side)
Fairmount (Investor)
Hansoh Pharmaceutical Group Co., Ltd. (Investor)